Curated News
By: NewsRamp Editorial Staff
October 14, 2026

SS Innovations Submits FDA Response for SSi Mantra Surgical Robot

Discuss on Substack
Original Source

TLDR

  • SS Innovations advances SSi Mantra toward U.S. market, gaining edge in affordable surgical robotics with FDA review expected in Q1 2027.
  • SS Innovations submitted an FDA 510(k) response for SSi Mantra on Oct 5, 2026, including expanded human clinical and bridging study data.
  • SS Innovations aims to make robotic surgery affordable and accessible, improving global healthcare by expanding access to advanced surgical care.
  • SSi Mantra features up to five robotic arms and 40 instruments, and has been clinically validated in over 190 surgical procedures in India.

Impact - Why it Matters

This news matters because it signals a potential breakthrough in making robotic surgery more accessible and affordable in the United States. The FDA's clearance of the SSi Mantra would introduce a cost-effective alternative to existing surgical robotic systems, which could lead to lower healthcare costs and increased adoption of minimally invasive procedures. For patients, this means greater access to advanced surgical care with potentially faster recovery times and reduced complications. For the medical industry, it represents a step toward democratizing robotic surgery, especially in underserved markets. SS Innovations' progress also highlights the growing global competition in surgical robotics, which can drive innovation and improve patient outcomes worldwide.

Summary

SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced a significant regulatory milestone in its quest to bring the SSi Mantra surgical robotic system to the United States. On October 5, 2026, the company submitted its response to a request for additional information from the U.S. Food and Drug Administration (FDA) concerning its 510(k) submission for the SSi Mantra. The response package includes final data from an expanded human clinical and human factors validation study, along with a bridging study completed in August 2026 at Hospital Internacional de Colombia, a member of the Mayo Clinic Care Network. The current submission covers the initial indication of cholecystectomy, or gallbladder removal.

SS Innovations anticipates that the FDA will complete its review of the response and the 510(k) submission in the first quarter of 2027. This would mark a major step toward introducing the SSi Mantra system to the U.S. market. The SSi Mantra is a modular, multi-arm robotic system featuring 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a touch panel monitor. It also offers an optional SSi MantrAsana tele-surgeon console for telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries, and has been clinically validated in India in more than 190 different types of surgical procedures. For more information, visit ssinnovations.com or LinkedIn.

Headquartered in India, SS Innovations is a U.S. company focused on making robotic surgery affordable and accessible globally. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.

Source Statement

This curated news summary relied on content distributed by NewMediaWire. Read the original source here, SS Innovations Submits FDA Response for SSi Mantra Surgical Robot

Blockchain registration record for this content